MétaCan
Menu
Back to cohort

A 2-Stage, Single-Arm, Phase 2 Study of Epigallocatechin Gallate–Enriched Green Tea Drink as a Maintenance Therapy in Women With Advanced-Stage Ovarian Cancer

2014· article· en· W2319325812 on OpenAlexaffabout
Dominique Trudel, David P. Labbé, Monica Araya-Farias, Alain Doyen, Laurent Bazinet, Thierry Duchesne, Marie Plante, Jean‐Pierre Grégoire, Marie‐Claude Renaud, Dimcho Bachvarov, Bernard Têtu, Isabelle Bairati

Bibliographic record

VenueObstetrical & Gynecological Survey · 2014
Typearticle
Languageen
FieldMedicine
TopicOvarian cancer diagnosis and treatment
Canadian institutionsUniversité LavalMcGill UniversityHôtel-Dieu de QuébecHôpital du Saint-SacrementToronto General HospitalUniversity Health Network
Fundersnot available
KeywordsMedicineTaxaneDebulkingOvarian cancerStage (stratigraphy)Serous fluidOncologyInternal medicineCancerChemotherapyClinical trialSurgeryGynecologyBreast cancer

Abstract

fetched live from OpenAlex

First-line treatment of epithelial ovarian cancer includes debulking surgery and platinum/taxane combination chemotherapy. The initial rate of response is high, but most patients eventually die of a recurring disease. It has been suggested that green tea may be useful to maintain response to first-line therapy after primary treatment. The anticancer actions of green tea for ovarian cancer and other types of cancer have been attributed to the catechins, epigallocatechin gallate (EGCG) and epicatechin gallate. Double-brewed green tea (DBGT) is an EGCG-enriched tea that has significant antitumor activity. This trial was a 2-stage, single-arm, phase 2 study that assessed the efficacy and safety of DBGT as a maintenance treatment in women with advanced-stage ovarian cancer who were in complete clinical remission after cytoreductive surgery and first-line chemotherapy. The trial was conducted at a single center, the Centre Hospitalier Universitaire de Québec. All patients received 500 mL of DBGT to drink daily until recurrence or during a follow-up of 18 months. The primary study endpoint was the absence of recurrence at 18 months. The study used an intention-to-treat design. From 2007 to 2011, a total of 306 women were identified with International Federation of Gynecology and Obstetrics stage III to IV serous or endometrioid ovarian cancer who had undergone complete response after debulking surgery followed by 6 to 8 cycles of platinum/taxane chemotherapy. Of these women, 257 were not eligible and 23 were not evaluated for eligibility. Among the remaining 26 eligible women, 10 declined to participate and 16 enrolled in the first stage. According to the treatment plan, if 7 or fewer women were free of recurrence at 18 months of follow-up, the trial was stopped. Otherwise, enrollment would continue to a total of 46 patients. The trial was terminated after the first stage at 18 months of follow-up because only 5 of the 16 women were free of recurrence. The median adherence of the women to DBGT was 98.1% (interquartile range, 89.7%–100%). However, 6 women (37.5%) discontinued participation before the end of the follow-up. There was no severe toxicity. All adverse events were of grade 1. These data suggest that DBGT supplementation is not a promising maintenance therapy for women with advanced-stage ovarian cancer after first-line treatment.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Insufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.249
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.002
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.043
GPT teacher head0.321
Teacher spread0.278 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2014
Admission routes2
Has abstractyes

Explore more

Same venueObstetrical & Gynecological SurveySame topicOvarian cancer diagnosis and treatmentFrench-language works237,207